(Last updated : 2025-11-25 15:40:34)
  NAKAYAMA Takayuki
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine  Department of Urology
   Position   Assistant Professor
■ Published papers
1. Original article  Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
2. Original article  Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
3. Other  Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2025/05 Link
4. Original article  Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
5. Original article  Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
Display all(6)
■ Academic conference presentation
1. Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. (ポスター掲示,一般) 2025/09/26
2. Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. (ポスター掲示,一般) 2025/04/27
3. Primary renal tumor response in patients treated with first-line systemic therapy for advanced renal cell carcinoma. (ポスター掲示,一般) 2024/04/26